Other
In-process research and development impairments
Johnson & Johnson In-process research and development impairments decreased by 55.6% to $36.00M in Q1 2026 compared to the prior quarter. Over 3 years (FY 2021 to FY 2025), In-process research and development impairments shows a downward trend with a -55.2% CAGR.
Analysis
StatementIncome Statement
SectionOther
CategoryCapital Allocation
SignalContext dependent
VolatilityVolatile
First reportedQ1 2021
Last reportedQ1 2026Apr 22, 2026
How to read this metric
Higher values indicate significant recent M&A activity focused on acquiring external innovation, while lower values suggest a focus on internal development.
Detailed definition
This metric captures the costs associated with research and development projects acquired through business combinations...
Peer comparison
Companies in highly acquisitive sectors like biotech often report these charges periodically, whereas organic-growth firms report minimal amounts.
Metric ID:
other_research_and_development_in_process1Historical Data
18 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $225.00M | $225.00M | $225.00M | $0.00 | $173.00M | $49.00M | $0.00 | $206.00M | $58.00M | $0.00 | $194.00M | $0.00 | $17.00M | $0.00 | $0.00 | $0.00 | $81.00M | $36.00M |
| QoQ Change | — | +0.0% | +0.0% | -100.0% | — | -71.7% | -100.0% | — | -71.8% | -100.0% | — | -100.0% | — | -100.0% | — | — | — | -55.6% |
| YoY Change | — | — | — | -100.0% | -23.1% | — | — | — | -66.5% | -100.0% | — | -100.0% | -70.7% | — | -100.0% | — | +376.5% | — |
Range$0.00 – $225.00M
CAGR-35.0%
Avg YoY Growth-23.0%
Median YoY Growth-85.3%
In-process research and development impairments at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's in-process research and development impairments?
- Johnson & Johnson (JNJ) reported in-process research and development impairments of $36.00M in Q1 2026.
- What is the long-term trend for Johnson & Johnson's in-process research and development impairments?
- Over 3 years (2021 to 2025), Johnson & Johnson's in-process research and development impairments has grown at a -55.2% compound annual growth rate (CAGR), from $900.00M to $81.00M.
- What does in-process research and development impairments mean?
- The value of research and development projects acquired from other companies that are not yet finished.